Foliglurax

• Business
• Denmark
• Netherlands
• Pharma & Biotech

H. Lundbeck A/S to acquire Prexton Therapeutics BV for EUR 100 million upfront and up to EUR 805 million in development and sales milestones paid later

Lundbeck will make an upfront payment of EUR 100 million and the deal terms also include up to EUR 805…